Clinical trials: Hematological Malignancies
Hematologic Malignancies, Multiple Myeloma
Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma
This is an open-label, multicenter, phase 1, dose escalation study of MLN4924 in adult patients with lymphoma or multiple myeloma.
- Conditions
- Hematologic Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma
- Trial name
- NCT00722488
- Testing
- MLN4924
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Diffuse Large B-Cell Lymphoma
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
This study will evaluate the effectiveness of fostamatinib (200 mg twice a day) in patients with worsening or unmanageable lymphoma with a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (abbreviated as DLBCL)
- Trial name
- NCT01499303
- Testing
- Fostamatinib
- Where
- 21 sites in United States, United Kingdom
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Hematological Disorder
Intervention to Address Psychosocial Needs Among Socially Disadvantaged Older Adults With Cancer
The purpose of this study is to convene a group of diverse North Carolina-based community representatives (patients, caregivers, leaders of faith-based organizations, social workers, and patient navigators) to inform the…
- Trial name
- NCT05828654
- Testing
- Focus Group Discussions and Semi-structured Interviews, Training community lay navigators
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients
This phase II trial studies fentanyl buccal tablet or morphine to see how well it works compared to a placebo in controlling shortness of breath during or after physical activity in cancer patients.
- Trial name
- NCT04188418
- Testing
- Fentanyl Citrate Buccal Tablet, Morphine, Physical Performance Testing
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Blood Cancer
Development of a Multi-biomarker Panel for Prognostic Stratification and Treatment Response Prediction in Acute Graft Versus Host Disease of the Gut
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a life-saving treatment for many malignant hematologic diseases.
- Trial name
- GUT-PREDICTION (NCT07305090)
- Testing
- Adult and pediatric patients with hematological diseases treated with allogeneic hematopoietic cell transplantation
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Platelet Transfusion, Palliative Care
Retrospective Descriptive Study of Platelet Transfusion in Patients With Palliative Hematologic Malignancies at the University Hospital of Besançon
Development of palliative care is less effective for patients with hematologic malignancies. Limited data is available for end of life care in this population, moreover with thrombocytopenic patients.
- Trial name
- NCT03814486
- Testing
- descriptive
- Where
- France
- Volunteers
- 119 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
This phase II trial studies the side effects of a cord blood transplant using dilanubicel and to see how well it works in treating patients with human immunodeficiency virus (HIV) positive hematologic (blood) cancers.
- Conditions
- Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT04083170
- Testing
- Fludarabine, Cyclophosphamide, Thiotepa
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Fred Hutchinson Cancer Center
Neoplasms
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
This is an open-label repeat dose, multicenter, 2-part study to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) for GSK525762 given once-daily (QD) orally.
- Trial name
- NCT01943851
- Testing
- GSK525762
- Where
- 15 sites in United States, Australia and 3 more
- Volunteers
- 111 people
- Sponsor
- GlaxoSmithKline
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Vincristine Pharmacokinetics in Infants
This pilot trial compares drug exposure levels using a new method for dosing vincristine in infants and young children compared to the standard dosing method based on body surface area (BSA) in older children.
- Trial name
- NCT05359237
- Testing
- Biospecimen Collection, Vincristine
- Where
- 29 sites in United States, Australia and 1 more
- Volunteers
- 83 people
- Sponsor
- Children's Oncology Group
Hematologic Malignancies
Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets
In the transplant community, there is debate regarding the most appropriate food services for stem cell transplant patients. Recommendations regarding the use of low bacterial diets have been based on theoretical concepts of…
- Trial name
- NCT01687231
- Testing
- Non-neutropenic Diet
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Duke University
Hematologic Malignancies
Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML.
- Trial name
- NCT04546945
- Testing
- CD56
- Where
- 2 sites in Egypt
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Asmaa Hassan mohamed Abdel Mawjoud
Lymphoma, Lymphoid Hematological Malignancies
Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)
The INTeRCePT 2 study aims to develop a predictive assay to determine which patients with B cell lymphoma are most likely to respond to CAR T cell therapy.
- Trial name
- NCT07472972
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich
Graft -Versus-host-disease
CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation
This is a randomized, multisite, Phase II study designed to compare the 1-year GVHD-free survival of the control arm (no axatilimab) to the experimental arm (axatilimab) after myeloablative allogeneic HCT.
- Trial name
- ABRAXAS (NCT07808112)
- Testing
- Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Medical College of Wisconsin
Leukemia, Lymphoma
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
The purpose of this study is: 1. To establish the maximally tolerated dose (MTD) of intravenous busulfan (Busulfan®) in combination with fludarabine as conditioning regimen for transplantation with in-vivo T-cell depletion. 2.
- Conditions
- Leukemia, Lymphoma, Myeloma
- Trial name
- NCT00943319
- Testing
- Busulfan, Fludarabine, Campath
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Chicago
Multiple Myeloma, Relapsed Hematologic Malignancy
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
This study will evaluate the feasibility of a digital health coaching program for adults with relapsed or refractory multiple myeloma (R/R MM). One hundred adults with R/R MM will be enrolled at The University of Washington.
- Trial name
- NCT05956457
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Pack Health
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
This study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.
- Conditions
- Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01474681
- Testing
- HSC835
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Stem Cell Transplantation
Adherence, Viability, Clinical Evolution and Therapeutic Efficacy in Patients Undergoing Bone Marrow Transplantation
Hematological neoplasms originate from the differentiation and proliferation of abnormal lymphatic or myeloid cells that alter the constitution of elements of the blood, bone marrow and lymph nodes.
- Trial name
- NCT06134297
- Testing
- Cycle ergometer, Strength Training - elastic band and shin guards, Cycle ergometer, elastic band and shin guards
- Where
- Brazil
- Volunteers
- 93 people
- Sponsor
- Federal University of Health Science of Porto Alegre
Hematologic Malignancies
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.
- Trial name
- NCT03537482
- Testing
- APG-2575
- Where
- 5 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Hematologic Malignancy
Phase II Study of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adult Patients
This study aimed to evaluate the efficacy and safety of myeloablative double unit umbilical cord blood transplantation (dUCBT) in adult patients with hematologic malignancies.
- Trial name
- NCT02385955
- Testing
- Myeloablative double unit cord blood transplantation
- Volunteers
- 39 people
- Sponsor
- Seoul National University Hospital
Gastrointestinal Cancer, Hematologic Cancer
SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
SURGE aims to increase representation in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies.
- Conditions
- Gastrointestinal Cancer, Hematologic Cancer, Thoracic Cancer
- Trial name
- SURGE (NCT05375643)
- Testing
- SURGE
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Nadine Jackson, MD, MPH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.